Mapping data with payer needs. How to solve the data puzzle.
Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer perspective, the ‘data puzzle’ is a complex one to solve. Payers want to see data on safety, efficacy, effectiveness, affordability and patient population - but in varying degrees. The disparate payer population is demanding more and better evidence, so what action plan is needed? Find out how drug companies should respond to payer nuances and evolve targeted data strategies that actually succeed.
Report Overview Pulling the Data Puzzle Together: Being Payer-Centricspecifically looks at the growing importance of data in meeting the evolving needs of payers. Based on interviews with 8 senior market access and payer strategy experts from across the pharma industry, it reveals the datasets of most value, and offers practical guidance for building a payer-centric data strategy.
Report Features - A breakdown of the 5 most common payer archetypes and their various goals and data needs. Also discover the subtle but important differences between European and North American payer data requirements. - Clarification on the datasets payers are most actively seeking and their significance within the decision-making process. What is the optimum balance of clinical, commercial and patient outcomes data? - Insight into building a case for RWD applications including data components and targeted objectives for payer engagement. - Expert views on how pharma should pull the data puzzle together including the key people and roles required, core data infrastructure requirements and the ideal company culture. - Exploration of the relationship between payer-centricity and patient-centricity. Are these interdependent or mutually exclusive?
Key Benefits - A joined-up plan: Understand how to better integrate payer needs into the drug commercialisation process and market access strategy. - Improved market access: Use payer archetypes to segment your data strategy and provide a more coherent way forward. - Get ahead of the pack: Engage earlier in the payer communication process with relevant, timely and targeted evidence provision. - Overcome concerns: Meet payer needs more closely and offer reassurance (before they attempt to fill the gaps themselves) with the information that addresses their challenges. - Up your game: Discover best practice for frameworks and payer advisory boards, identify evidence gaps and establish a road map and action plan. - Upskill your team: Understand the company roles, responsibilities and skill sets needed to drive forward a sustainable, payer-centric data strategy.
Why is data the key to payer engagement? When game-changing drugs are not getting reimbursed, improving market access becomes the most important goal – not just for pharma but ultimately for patients too. Today data sits at the very core of market access and payer market agreements, and pharma must utilise its power more effectively to make a difference. That means converting data volume into value, improving data quality and relevance for payers, and making a robust case for every drug. Yes, the balance of cost savings and patient outcomes is a delicate one, but when outcomes based agreements are the ‘new normal’, data is the key to fulfilling promises and achieving long-term success.
Key Questions Answered - How is real world data impacting payer priorities and decision-making? - Do RCTs still have a place – and if so, how does this fit with what payers want to see? - Which economic and health data types are payers most interested in? - What should your payer-centric data strategy look like? - Which data gaps must be filled to reduce payer uncertainty and improve patient access? - How is data shaping and evolving key roles within market access and beyond? - How should clinical, commercial and economic data be put together to resolve the payer data puzzle?
Expert Views The experts interviewed for this report are responsible for market access, payer strategy and evidence generation in leading pharma and healthcare consulting companies. - Mike Bellis: Partner, PEN CX (Formerly Customer Experience Lead for Pfizer Europe) - Roy Bentley: Independent Consultant, Market Access & Healthcare Strategy- Charles Hampsey: Director, Payer Marketing, Daiichi Sankyo - Anders Holmen Møller: Global HEOR Manager, LEO Pharma - Klaas Postema: Senior Director, Market Access & Pricing Generics, Teva - Mete Saylan: Market Access Director, Bayer - Nilhan Uzman: Strategic Payer Evidence Specialist, Roche - Simone Wyss: Head, EUCAN GI Market Access, Takeda
3 Key Quotes “Some payers are more experienced now in that they can understand models and data provided by pharma. There are more experienced and well-trained payers who are able to discuss the data provided. Some of them have the intention to make their own research to understand the disease condition and potential cost/benefits.” Mete Saylan: Market Access Director, Bayer
“Market Access is expected to become the foundation of the pharmaceutical company in the future and replacing the two concepts – Marketing and Medical – that are driving company growth today.”Nilhan Uzman: Strategic Payer Evidence Specialist, Roche
“We have used archetyping for several years now, and so have other major companies, but never before has it been more applicable.” Anders Holmen Møller: Global HEOR Manager, LEO Pharma
Who Would Benefit from This Report? - Market access teams evolving payer-centric strategies - Brand marketing departments seeking new ways to edge ahead - Senior leadership teams looking at technology and role development - IT teams responsible for data collection, processing and access - Payer liaison specialists seeking to meet all requirements and fill gaps - R&D planning trial conversion into real world data collection points - Health economics and outcomes research (HEOR) professionals needing more robust, relevant analysis
Content Highlights - Executive Summary - Research Methodology - Experts interviewed - The rising significance of evidence on value - From volume to value - The availability of data - Data availability and decision-making - Key Insights - Data’s influence on payer decision-making - Data’s influence on healthcare authorities - Guaranteeing the quality of data - The data components of evidence - Key Insights - Evidence expansion: regulator vs. payer - The expanding number of RWD applications - The data types that payers seek - Health outcomes and drug effectiveness - Affordability - The patient population - Meeting data objectives during payer engagement - Key Insights - Identifying the data needs of payers - Integrating the payer perspective - Tailoring the communication of data to the individual payer - Completing the data puzzle with innovative contracts - Key Insights - Innovative contracting solutions - Opportunities in innovative contracting - Key factors to pull the data puzzle together - Key Insights - Data capabilities and infrastructure - People, positions and partnerships - A culture of payer-centricity - Enhancing the data puzzle - Key Insights - Patient-centricity at the heart of payer-centricity - A long-term, holistic approach to value - Prevention - Conclusion
Our reports have been used by over 10K customers, including:
KEY FINDINGS Cannabis is a psychoactive drug which is mainly used for medicinal and recreational purposes. The global cannabis testing market is expected to rise at a CAGR of 11.44% over the forecast period of 2018-2026. The market is mainly being driven by an increase in the number of testing facilities acquired as a strategic...
KEY FINDINGS Text Analytics Market in Europe is expected to exhibit a substantial growth over the forecast period of 2018-2026 by growing at a CAGR of 19.80%. Monetizing of social media analytics, the emergence of multilingual text analytics to break the language barrier, growing social media and smartphone users and the...
KEY FINDINGS Asia-Pacific dominated the global polyolefin market by accounting for the highest revenue share in 2017, and it is expected to continue its dominance throughout the forecast period of 2018-2026 by exhibiting a CAGR of 6.85%. MARKET INSIGHTS The availability of cheap skilled labour...
KEY FINDINGS The Global population health management market is expected to rise at a CAGR of 20.78% over the forecast years of 2018-2026. The key factors driving the market growth are increasing healthcare expenditure, government spending, rising need for cost-effective healthcare for the growing geriatric population, the...
KEY FINDINGS Cannabis testing is majorly carried out to detect the presence of heavy metals, impurities, residual solvents, pesticides or chemicals in order to assure the safety of cannabis for medicinal use. The North American cannabis testing market is expected to grow at a healthy CAGR of 10.51% over the forecast years...
KEY FINDINGS The global text analytics market is predicted to grow at a CAGR of 17.44% during the forecast period of 2018-2026. The major factors contributing to this market growth are increasing industry-specific applications of the market and monetization of social media analytics. MARKET INSIGHTS The...
Date=201704 Publisher=FirstwordPharma Price=1000
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.